# Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Canonical URL: https://biopharmsignal.com/news/SHC/sotera-health-delivers-strong-first-quarter-2026-results-and-reaffirms-2026-outlook
Ticker: SHC
Company: Sotera Health
Source: Sotera Health
Published: 2026-05-05 11:04 EST
Original Source URL: https://investors.soterahealth.com
## Summary

Q1 2026 net revenues increased 10.0%, or 6.5% on a co nstant currenc y basis, compared to Q1 2025 Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025 Q1 2026 Adjusted EBITDA ( 1) increased 10.5%, or 6.9% on a

## Article Body
Q1 2026 net revenues increased 10.0%, or 6.5% on a co nstant currenc y basis, compared to Q1 2025 Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025 Q1 2026 Adjusted EBITDA ( 1) increased 10.5%, or 6.9% on a
## Recent Company News
- 2026-05-05 11:04 EST — [Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook](https://biopharmsignal.com/news/SHC/sotera-health-delivers-strong-first-quarter-2026-results-and-reaffirms-2026-outlook) — Source: Sotera Health
- 2026-05-05 11:00 EST — [Sotera Health Announces Leadership Transition](https://biopharmsignal.com/news/SHC/sotera-health-announces-leadership-transition) — Source: Sotera Health
- 2026-04-21 11:46 EST — [Sotera Health Announces First-Quarter 2026 Earnings Release Date](https://biopharmsignal.com/news/SHC/sotera-health-announces-first-quarter-2026-earnings-release-date) — Source: Sotera Health
- 2026-03-16 11:00 EST — [Sotera Health Appoints Kenneth D. Krause to the Board of Directors](https://biopharmsignal.com/news/SHC/sotera-health-appoints-kenneth-d-krause-to-the-board-of-directors) — Source: Sotera Health
- 2026-03-04 21:51 EST — [Sotera Health Announces Secondary Offering of Common Stock](https://biopharmsignal.com/news/SHC/sotera-health-announces-secondary-offering-of-common-stock) — Source: Sotera Health
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)